jRCT2031240681进行中（未招募）不适用
An open-label pharmacokinetic study of TS-172 in patients on hemodialysis
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Single Arm Study
- 干预模型
- Single Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 18age old over 至 75age old not（—）
- 性别
- Male
入选标准
- •(1) Japanese male patients (outpatients) with chronic kidney disease receiving hemodialysis (HD or HDF) 3 times a week for at least 12 weeks prior to the screening test
- •(2) Patients aged >= 18 and < 75 years at the time of obtaining informed consent
排除标准
- •(1) Patients with gastric or intestinal ulceration or a history of them within the past year prior to the date of initiation of treatment, or patients with inflammatory bowel disease or irritable bowel syndrome, or a history of these within the past 5 years prior to the date of initiation of treatment
- •(2) Patients scheduled for renal transplantation, home hemodialysis or change of dialysis facility (transfer or temporary dialysis at other hospital) during the study period
- •(3) Patients who frequently experience diarrhea (defined as Bristol Stool Scale score of 6 or higher)
研究者
相似试验
进行中（未招募）
1 期
A pharmacokinetic study of TS-142 in patients with hepatic impairmentInsomniaJPRN-jRCT2031220463Mita Seiji24
已完成
1 期
A clinical pharmacology study of TS-142 in patients with obstructive sleep apnea hypopnea.Obstructive sleep apnea hypopneaJPRN-jRCT2031200373Mita Seiji40
未知
4 期
Clinical Pharmaclogical study of TS-071 in Patient With Type 2 Diabetetes Mellitus(Evaluation of glycemic variability using continuous glucose monitoring)Type 2 Diabetes MellitusJPRN-jRCT1080222497Taisho Pharmaceutical co., LTD40
已完成
2 期
Safety, Pharmacokinetic, and Pharmacodynamic Study of TS-142 in Healthy SubjectsHealthy VolunteerNCT04087707Taisho Pharmaceutical Co., Ltd.23
进行中（未招募）
不适用
Pharmacokinetic Study in Children Aged 1 to 17 Years After Administration of a Single Dose of TelavanciGram-Positive Bacterial InfectionsMedDRA version: 18.0Level: LLTClassification code 10053021Term: Gram-positive bacterial infectionSystem Organ Class: 100000004862EUCTR2015-002218-60-Outside-EU/EEATheravance Biopharma Antibiotics, Inc.32